APA (7th ed.) Citation

B, B., KK, S., C, S., S, L., AN, P., J, M., . . . PE, H. (2025). AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers. Cancer discovery, 15(1), 139. https://doi.org/10.1158/2159-8290.CD-24-0887

Chicago Style (17th ed.) Citation

B, Belmontes, et al. "AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers." Cancer Discovery 15, no. 1 (2025): 139. https://doi.org/10.1158/2159-8290.CD-24-0887.

MLA (9th ed.) Citation

B, Belmontes, et al. "AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers." Cancer Discovery, vol. 15, no. 1, 2025, p. 139, https://doi.org/10.1158/2159-8290.CD-24-0887.